Jenoptik review of “MORE VALUE” Agenda 2025 at mid-stage: Execution well on track

• Accelerated focus on core markets
• Revenue target of about 1.2 billion euros for 2025 confirmed
• Profitability target (EBITDA margin) upgraded

“Jenoptik is on a very good path in its transformation into a globally leading, pure-play photonics group and has established strong growth platforms,” says Dr. Stefan Traeger, President & CEO of JENOPTIK AG. “At about the mid-stage of implementing our Agenda 2025, we have significantly strengthened our position in our core businesses, which already account for more than 85 percent of group revenue. Moreover, we have grown organically by around 10 percent on average, more than expected. We are therefore raising our profitability target and now expect to achieve an EBITDA margin of 21-22 percent in 2025.”

Agenda 2025 “MORE VALUE”

At the heart of our agenda “More Value,” Jenoptik is focusing its leading technology capabilities on the three high-growth semiconductors & electronics, life science & medical technology, and smart mobility markets. As an “enabler,” the company is poised to generate substantial added value (“MORE VALUE”) for customers, employees, and shareholders, aiming for above average growth and profitability gains.  

As part of the strategic rollout, the Group has tailored its portfolio to the core photonics markets, in part by the sale of VINCORION (defense) and the acquisition of TRIOPTICS (electronics) and BG Medical/SwissOptic (medical technology/semiconductors). Jenoptik can thus build on strong platforms for future profitable growth.

Financial targets 2025: revenue target confirmed; profitability expectation raised

The Group continues to target revenue of around 1.2 billion euros in 2025. The plan does not include further acquisitions or divestments. In light of better-than-expected organic development, the EBITDA margin target for 2025 has been raised from around 20 percent to between 21 and 22 percent.

Transformation largely completed; focus on organic growth

Jenoptik has largely completed its transformation from a diversified industrial company to a leading and focused photonics group. By strengthening its core businesses, Jenoptik has significantly increased the share of revenue generated with key long-term partners. Until 2025, the company plans to focus its investments primarily on organic growth. For example, the construction of a new factory for the semiconductor equipment industry in Dresden is expected to be completed in 2025, while a new site for the medical technology business in Berlin opened in June 2023.

Jenoptik combines its investments in Prodomax and HOMMEL-ETAMIC in the Non-Photonic Portfolio Companies segment. The aim is still to sell the automation specialist Prodomax, which focuses on the automotive industry, by 2025 at the latest. The further development of HOMMEL-ETAMIC (industrial metrology) can take place either within or outside the Group.  

Jenoptik Capital Markets Day 2023

JENOPTIK AG will hold its Capital Markets Day on 1 December 2023 at 9:00 am (CET). More information can be found on the Jenoptik website.

This press release may contain statements relating to the future which are based on current assumptions and forecasts made by the corporate management of the Jenoptik Group. A variety of known and unknown risks, uncertainties, and other factors may cause the actual results, the financial situation, the development, or the performance of the company to diverge significantly from the information provided here. Such factors may include geopolitical conflicts, changes in currency exchange rates and interest rates, pandemics, the introduction of competing products, or a change in business strategy. The company does not assume any obligation to update such forward-looking statements in the light of future developments.